As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
|Articles|December 18, 2015
Isis Pharmaceuticals Changes Company Name
December 18, 2015.
Advertisement
Isis Pharmaceuticals (Arlsbad, CA) today announced that the company has changed its name to Ionis Pharmaceuticals (pronounced "eye-OH-nis") for obvious reasons.
Lynne Parshall, chief operating officer at Ionis, said: "We decided to change our company name because, when people see or hear our name, we want them to think about the life-saving medicines we are developing."
In conjunction with the corporate name change, the company will trade on the NASDAQ Global Select Market under the new ticker symbol "IONS". In addition, it has a new website address:
Advertisement
Related to this article
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Why purpose is becoming the most important infrastructure in AI-driven health care technology.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
2
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
3
Viatris Acquires Pacira BioSciences for $1.65 Billion
4
Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
5